Oral News and Research

RSS

Acucela begins phase 2b/3 clinical trial of emixustat hydrochloride to treat GA associated with dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for sight threatening eye diseases, today announced that a phase 2b/3 clinical trial investigating emixustat hydrochloride in subjects with geographic atrophy associated with dry age-related macular degeneration has been initiated.

25 Apr 2013

WHO highlights threat of antimalarial drug resistance in Greater Mekong subregion

On World Malaria Day, 25 April, WHO recognizes significant accomplishments in preventing and controlling malaria, including in high-burden countries in sub-Saharan Africa, but highlights the threat of antimalarial drug resistance in south-east Asia's Greater Mekong subregion, where an emergency response is now being launched.

25 Apr 2013

Roundup: Calif. health care cuts attract opponents; Health law means fewer hours for Va. community college instructors

In the health care world, there's not a whole lot that insurers, doctors and union workers all agree on. But a new coalition of powerful Capitol players from all three groups is hoping to reverse recent budget cuts, pushed by Gov. Jerry Brown, to those who provide care to the poorest Californians.

25 Apr 2013

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia.

24 Apr 2013

Opinion pieces address polio eradication goal to be discussed at Global Vaccine Summit

Public and private sector representatives will meet this week in Abu Dhabi at the Global Vaccine Summit, hosted by His Highness General Sheikh Mohamed bin Zayed bin Sultan Al Nahyan, Crown Prince of Abu Dhabi, in partnership with U.N. Secretary-General Ban Ki-moon and Bill Gates, co-chair of the Bill & Melinda Gates Foundation.

24 Apr 2013

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals for the treatment of hepatitis C virus infection, continue to demonstrate high sustained viral response rates against genotype 1 HCV, across patient types.

24 Apr 2013

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.

24 Apr 2013

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

24 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Gilead Sciences, Inc. today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands.

23 Apr 2013

U.S. Supreme Court to hear oral arguments to decide fate of anti-prostitution pledge

"On Monday, the Supreme Court hears oral arguments in a case that will decide if recipients of government aid can be forced to oppose prostitution -- or potentially any other issue as a contingency of receiving U.S. funds," The Nation reports.

23 Apr 2013

Oncology nurses explore how to better combat patient fatigue

They are key members of the healthcare team who face ongoing challenges on how best to provide optimum care to patients affected by cancer. Oncology nurses at The Cancer Institute of New Jersey continually strive to improve patient care and have recently explored how to better combat patient fatigue, the importance of documenting sleep-wake disturbances and the development of a toolkit to help patients better follow their oral treatment schedule during clinical trials.

23 Apr 2013

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Merck today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibb's investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus infection, genotype 1.

23 Apr 2013

Women & Infants Hospital physician to study treatment options for heavy menstrual bleeding

Kristen A. Matteson, MD, MPH, of the Department of Obstetrics and Gynecology at Women & Infants Hospital and assistant professor of obstetrics and gynecology at The Warren Alpert Medical School of Brown University, has earned a $1.6 million grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health to study the effectiveness of two treatments options for heavy menstrual bleeding.

23 Apr 2013

$Study shows 30.4% of hip fracture patients in India died within one year$

Study shows 30.4% of hip fracture patients in India died within one year

In various studies across different countries the reported one year mortality risks after hip fracture can vary anywhere from 5 to 50 %. In India, however, there has been little research on the risk of mortality and functional impairment following hip fracture.

23 Apr 2013

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

22 Apr 2013

Aeterna enters into agreements to transfer manufacturing license for Cetrotide to Merck KGaA

Aeterna Zentaris Inc. today announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide® product.

22 Apr 2013

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights from Merck, known as MSD outside the United States and Canada, to develop and commercialize MK-0657, a small molecule NMDA receptor subunit 2B (NR2B) antagonist for all human indications, including depression.

22 Apr 2013

Study indentifies unmet medical need for treatment of patients with chronic pain and dysphagia

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of a research study, conducted with an independent market research firm, that identified a significant unmet medical need for improved treatments for patients with chronic pain and dysphagia/odynophagia. In clinical practice, dysphagia is most often defined as difficulty in swallowing and odynophagia is defined as pain upon swallowing.

22 Apr 2013

National Foundation for Infectious Diseases to host 16th Annual Conference on Vaccine Research

The National Foundation for Infectious Diseases will host the 16th Annual Conference on Vaccine Research, April 22-24, 2013, at the Hyatt Regency Inner Harbor in Baltimore, MD.

22 Apr 2013

Oral News and Research

Acucela begins phase 2b/3 clinical trial of emixustat hydrochloride to treat GA associated with dry AMD

WHO highlights threat of antimalarial drug resistance in Greater Mekong subregion

Roundup: Calif. health care cuts attract opponents; Health law means fewer hours for Va. community college instructors

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Opinion pieces address polio eradication goal to be discussed at Global Vaccine Summit

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

U.S. Supreme Court to hear oral arguments to decide fate of anti-prostitution pledge

Oncology nurses explore how to better combat patient fatigue

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Women & Infants Hospital physician to study treatment options for heavy menstrual bleeding

Study shows 30.4% of hip fracture patients in India died within one year

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Aeterna enters into agreements to transfer manufacturing license for Cetrotide to Merck KGaA

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Study indentifies unmet medical need for treatment of patients with chronic pain and dysphagia

National Foundation for Infectious Diseases to host 16th Annual Conference on Vaccine Research

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News